Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech to Host Webcast Conference Call on Wednesday October 5, 2005
Oct 4, 2005
|
64.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will hold a webcast teleconference tomorrow at 8:30 a.m. Eastern time on Wednesday, October 5, 2005 to discuss Phase 3 clinical data.
Interested parties can listen to the live audio webcast, or the subsequent ...
|
|
|
Corgentech and AlgoRx Announce Merger Agreement
Sep 26, 2005
|
86.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif. and SECAUCUS, N.J., Sept 26, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) and AlgoRx Pharmaceuticals, Inc. today announced that they have entered into a definitive merger agreement to create a late-stage company with a deep pipeline of clinical products that will be largely focused on develop...
|
|
|
Corgentech to Host Webcast Conference Call on Monday, September 26, 2005
Sep 23, 2005
|
65.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Sept 23, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will hold a webcast teleconference at 8:30 a.m. Eastern time on Monday, September 26, 2005 to discuss company news.
Interested parties can listen to the live audio webcast, or the subsequent archived recordin...
|
|
|
Corgentech Announces Second Quarter 2005 Financial Results
Jul 26, 2005
|
80.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 26, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today reported financial results for the second quarter and six months ended June 30, 2005.
"In the second quarter, we achieved important milestones in the development of our lead product candidate, NF-kappaB (NF-kB) Decoy for the tre...
|
|
|
Corgentech Initiates Enrollment in Additional Phase 1/2 Trial of New Drug Candidate for Eczema
Jul 21, 2005
|
71.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that the company has begun treating patients in its ex-U.S., multi-center Phase 1/2 clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug candidate for the treatment of atopic dermatitis, a chronic skin disease also kno...
|
|
|
Click here to download our most recent fact sheet.